Dr. Yang has over 20 years of industry experience in drug discovery and pre-clinical development of small molecules related to target selection through development candidate selection for antiviral, anti-inflammatory and oncology therapeutic indications.
Prior to joining Aldea, Dr. Yang was Vice President of Chemistry at Eiger BioPharmaceuticals, where he oversaw research and manufacturing functions. He previously served as Director and Head of Medicinal Chemistry at Sunesis Pharmaceuticals where he was responsible for scientific team management and multiple medicinal chemistry programs, including new technology development, hit identification and lead optimization to development candidate selection.
Before joining Sunesis, Dr. Yang was a Research Scientist at Gilead Sciences, responsible for design and synthesis of antiviral and antiretroviral compounds and a postdoctoral research associate at The Scripps Research Institute. Dr. Yang holds a PhD in Organic Chemistry from the University of California, Riverside.